Galecto Inc. Stock Price, News & Analysis

Galecto (NASDAQ: GLTO) presented data from its completed Phase 1b/2a GULLIVER-2 trial at The Liver Meeting 2022. The trial evaluated GB1211, a galectin-3 inhibitor, for severe liver diseases. Topline data showed GB1211 was well-tolerated, with encouraging clinical efficacy, including reduced liver enzyme levels and improved liver fat measurements. The results support further development of GB1211 in severe cirrhosis, addressing a critical unmet need for treatment options. A webinar is scheduled for November 8, 2022, to discuss the findings in detail.

Galecto, Inc. (NASDAQ: GLTO) announced a collaboration for a Phase 2 trial at Providence Cancer Institute to evaluate the safety and efficacy of GB1211, a galectin-3 inhibitor, combined with pembrolizumab (Keytruda). This investigator-initiated trial aims to counteract checkpoint inhibitor resistance in melanoma and head and neck squamous cell carcinoma (HNSCC) patients. The randomized trial will start in 2023, with top-line results expected by 2025. GB1211 has shown promise in previous studies, demonstrating a well-tolerated profile and potential anti-cancer effects.

Galecto, Inc. (NASDAQ: GLTO) announced a live conference call and webcast on November 8, 2022, at 8:00 am ET to discuss topline data from the GULLIVER-2 trial for liver cirrhosis. The trial assesses the safety and efficacy of GB1211, an oral galectin-3 inhibitor, in up to 54 participants with decompensated cirrhosis. The trial includes both randomized and open-label study parts, focusing on pharmacokinetics and therapeutic potential. Interested individuals can join the webcast through a provided link, and a replay will be accessible on the investor relations website.

Galecto, Inc. (NASDAQ: GLTO) announced positive results from its Phase 2a MYLOX-1 trial of GB2064 for myelofibrosis on September 29, 2022. Out of five evaluable patients, four showed a ≥ 1-grade reduction in collagen fibrosis after six months of GB2064 treatment, indicating potential disease modification. Patients also exhibited stable hematological parameters without the need for transfusions. The drug demonstrated a generally acceptable tolerability profile, though some patients discontinued due to adverse events. Company leadership highlighted these results as a proof of principle for GB2064's anti-fibrotic effects.

Galecto, Inc. (NASDAQ: GLTO), a biotechnology firm, announced participation in H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022. Management will engage in virtual 1x1 meetings with investors, and a webcast of the presentation will be available for replay on Galecto’s website. The company focuses on developing inhibitors for fibrosis and cancer, with four ongoing Phase 2 clinical trials targeting conditions like idiopathic pulmonary fibrosis and non-small cell lung cancer.

Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology firm, has published a study in the Journal of Cancer Research and Clinical Oncology that highlights the role of galectin-3 in cancer treatment. The research shows that high levels of galectin-3 are linked to reduced survival rates in cancer patients, suggesting that Galecto's oral candidate GB1211 could enhance the effectiveness of checkpoint inhibitors like atezolizumab. Ongoing Phase 2a trials evaluate GB1211’s performance in non-small cell lung cancer (NSCLC).

Galecto, Inc. (NASDAQ: GLTO) reported its Q2 2022 financial results, highlighting significant advancements in its clinical pipeline. The company completed enrollment in the Phase 2b GALACTIC-1 trial for idiopathic pulmonary fibrosis (IPF) and initiated the Phase 2a GALLANT-1 trial for non-small cell lung cancer (NSCLC). Cash and investments stood at approximately $85.9 million, expected to sustain operations into H2 2024. However, the net loss attributable to common stockholders increased to $16.9 million, or $(0.67) per share, compared to $12.3 million, or $(0.49) per share, in the prior year.

Galecto, Inc. (GLTO) has initiated the Phase 2a GALLANT-1 trial, enrolling the first patient to study GB1211, a galectin-3 inhibitor, in combination with Roche's atezolizumab for treating non-small cell lung cancer (NSCLC). This trial seeks to assess the efficacy of GB1211 in enhancing checkpoint inhibition. Pre-clinical studies indicate GB1211's potential to diminish tumor growth and metastasis. Topline data is expected in mid-2023, as Galecto continues its focus on targeted cancer therapies.

Galecto, Inc. (NASDAQ: GLTO) announced its participation at the Jefferies Healthcare Conference, scheduled for June 8-10, 2022, in New York City. The presentation will occur at 3:00 PM ET, and a live webcast will be available on Galecto's investor website. The company is dedicated to developing treatments for cancer and fibrosis, with ongoing clinical trials including GB0139 for idiopathic pulmonary fibrosis and GB2064 for myelofibrosis. For further details, visit their website.